Atara Biotherapeutics (ATRA)
Nasdaq Market Closed
Atara Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing cell-based medicines for patients with serious cancers and autoimmune diseases. The company operates in the US healthcare sector and is built around immunotherapy, particularly allogeneic T-cell approaches designed to harness the immune system against disease. Its work sits within a highly specialized part of biotech where research, manufacturing, and regulatory execution are central to commercial potential.
Atara’s pipeline includes programs aimed at hematologic cancers, solid tumors, and autoimmune conditions. Its named product candidates include tab-cel, ATA3431, and ATA3219. Tab-cel, also known as tabelecleucel, is associated with Epstein-Barr virus-driven disease and represents the company’s broader focus on off-the-shelf T-cell therapies. ATA3219 is a chimeric antigen receptor T-cell program, while ATA3431 is part of the company’s oncology-focused development efforts.
The company manages its business as a single operating and reportable segment: the development of therapeutics. Like many biotechnology firms at this stage, Atara’s value is closely tied to clinical trial progress, data readouts, manufacturing capabilities, regulatory interactions, and the potential for partnerships or commercialization. Investors typically assess the company through the prospects of its pipeline rather than diversified product revenue.
Atara is distinctive because it concentrates on advanced cell therapy platforms rather than conventional small-molecule or antibody medicines. Its strategy targets areas of high unmet medical need, where successful therapies can command significant clinical and commercial attention, but where development risk is also substantial.
Last updated
- Market Cap
- 86.77M
- P/E
- —
- P/FCF
- —
- P/S
- 3.75
- Enterprise Value
- 78.41M
- Sector
- Health Care
- Industry
- Biological Products, Except Diagnostic Substances
- Address
- 1280 RANCHO CONEJO BLVD, THOUSAND OAKS, CA, 91320
ATARA DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Atara Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ATRA
Bronstein, Gewirtz & Grossman LLC Urges Atara Biotherapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
DEADLINE ALERT for ATRA, COTY, SMCI, IBRX: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions
Bronstein, Gewirtz & Grossman LLC Urges Atara Biotherapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Deadline Alert: Atara Biotherapeutics, Inc. (ATRA) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Atara Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ATRA
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Graphic Packaging Holding Company Investors to Secure Counsel Before Important Deadline in Securities Class Action – GPK
Atara Biotherapeutics, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before May 22, 2026 to Discuss Your Rights – ATRA
UPST Investor Alert: Upstart Holdings Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Executives Allegedly Inflated AI Projections: Levi & Korsinsky
DEADLINE ALERT for ATRA, COTY, SMCI, IBRX: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions
Bragar Eagel & Squire, P.C. Reminds Atara Biotherapeutics, Inc. Investors They Have Until May 22nd to Seek Lead Plaintiff Role in Class Action Lawsuit
ROSEN, LEADING INVESTOR COUNSEL, Encourages Atara Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ATRA
Bronstein, Gewirtz & Grossman LLC Urges Atara Biotherapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Pomerantz Law Firm Announces the Filing of a Class Action Against Atara Biotherapeutics, Inc. and Certain Officers – ATRA
Shareholders that lost money on Atara Biotherapeutics, Inc.(ATRA) Urged to Join Class Action – Contact Levi & Korsinsky to Learn More
Bronstein, Gewirtz & Grossman LLC Urges Atara Biotherapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Atara Biotherapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - ATRA
ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Atara Biotherapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before May 22, 2026 to Discuss Your Rights – ATRA
- Market Cap
Market cap is the total value of a company's shares, calculated by multiplying the stock price by the number of shares outstanding.
- 86.77M
- Enterprise Value
Enterprise value is the total value of a company, including its market cap, debt, and cash.
- 78.41M
- P/E
P/E ratio compares a company's share price to its earnings per share.
- —
- P/B
P/B ratio compares a company's share price to its book value per share.
- -2.33
- P/S
P/S ratio compares a company's share price to its revenue per share.
- 3.75
- EV / EBITDA
EV/EBITDA measures a company's value compared to its earnings before interest, taxes, depreciation, and amortization.
- -13.16
- EV / Sales
EV/Sales measures a company's value compared to its total revenue.
- 3.39
- EPS
- -1.05
- Dividend Yield
Dividend yield shows how much a company pays in dividends each year compared to its share price.
- 0%
- P/FCF
Price-to-free-cash-flow ratio compares a company's share price to the cash it generates after expenses and investments.
- —
- P/CF
P/CF ratio compares a company's share price to the cash flow it generates from its operations.
- —
- Free Cash Flow
Free cash flow is the cash a company has left after covering operating costs and capital expenses.
- —
- ROE
ROE measures how effectively a company uses shareholders' equity to generate profit.
- 25.37%
- ROA
ROA measures how effectively a company uses its assets to generate profit.
- -47.34%
- Debt / Equity
Debt-to-equity ratio compares a company's total debt to its shareholders' equity.
- 0
- Current Ratio
Current ratio measures a company's ability to pay short-term debts using its short-term assets.
- 2.16
- Quick Ratio
Quick ratio measures a company's ability to pay short-term debts using cash and other easily available assets.
- 2.16
- Cash
Cash ratio measures a company's ability to cover short-term debts using only cash and cash equivalents.
- 1.48
- Avg Volume
Average volume shows the average number of shares traded over the last 30 trading days, helping indicate liquidity.
- 2.86M
- Fundamentals Snapshot Price
Fundamentals snapshot price is the stock price used when calculating the company's financial ratios and metrics.
- 9.63
Income Statement
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Revenue | 516K | 1.6M | 3.45M | 17.58M | 98.15M |
| Gross profit | 392K | 1.49M | 3.34M | 17.02M | 77.71M |
| Operating income | -3.37M | -2.56M | -3.57M | 3.2M | 38.8M |
| EBITDA | -3.34M | -2.51M | -3.54M | 3.43M | 40.6M |
| Net income | -4.15M | -3.41M | -4.3M | 2.39M | 38.01M |
| Basic EPS | -0.29 | -0.35 | -0.32 | 0.2 | 3.53 |
| Diluted EPS | -0.29 | -0.36 | -0.32 | 0.19 | 3.5 |
Balance Sheet
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Total assets | 20M | 20.24M | 30.17M | 36.9M | 62.04M |
| Total liabilities | 57.31M | 58.74M | 66.8M | 71.94M | 117.11M |
| Total equity | -37.31M | -38.5M | -36.63M | -35.04M | -55.07M |
| Cash & equivalents | 8.36M | 8.48M | 5.74M | 16.9M | 13.84M |
| Current assets | 12.17M | 12.21M | 18.43M | 24.77M | 27.04M |
| Current liabilities | 5.65M | 14.92M | 18.06M | 14.56M | 47.89M |
Cash Flow
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Operating cash flow | -3.07M | -5.7M | -9.79M | -7.32M | -28.14M |
| Investing cash flow | — | 8.44M | -2.42M | -5.07M | 17.2M |
| Financing cash flow | 2.95M | -3K | 1.05M | 15.3M | -250K |
| Change in cash | -122K | 2.74M | -11.16M | 2.92M | -11.19M |
| Kind | Filing | Date | Link |
|---|---|---|---|
| edgar index | 4 — Atara Biotherapeutics, Inc. | View Filing | |
| edgar index | 4 — Atara Biotherapeutics, Inc. | View Filing | |
| edgar index | 144 — Atara Biotherapeutics, Inc. | View Filing | |
| edgar index | 144 — Atara Biotherapeutics, Inc. | View Filing | |
| form 4 | Form 4 — Grant-Huerta Yanina | View Filing | |
| form 4 | Form 4 — Nguyen AnhCo | View Filing | |
| edgar index | SCHEDULE 13D/A — Atara Biotherapeutics, Inc. | View Filing | |
| edgar index | SCHEDULE 13G — Atara Biotherapeutics, Inc. | View Filing | |
| edgar index | 8-K — Atara Biotherapeutics, Inc. | View Filing | |
| edgar index | 10-Q — Atara Biotherapeutics, Inc. | View Filing | |
| edgar index | 424B5 — Atara Biotherapeutics, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 3 — Atara Biotherapeutics, Inc. | View Filing | |
| edgar index | 4 — Atara Biotherapeutics, Inc. | View Filing | |
| edgar index | 4 — Atara Biotherapeutics, Inc. | View Filing | |
| edgar index | SCHEDULE 13D/A — Atara Biotherapeutics, Inc. | View Filing | |
| form 3 | Form 3 — EcoR1 Capital, LLC | View Filing | |
| edgar index | SCHEDULE 13G — Atara Biotherapeutics, Inc. | View Filing | |
| edgar index | SCHEDULE 13G/A — Atara Biotherapeutics, Inc. | View Filing | |
| edgar index | 8-K — Atara Biotherapeutics, Inc. | View Filing | |
| edgar index | 144 — Atara Biotherapeutics, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| form 4 | Form 4 — EcoR1 Capital, LLC | View Filing | |
| form 4 | Form 4 — Huang James | View Filing | |
| form 4 | Form 4 — Panacea Innovation Ltd | View Filing | |
| form 4 | Form 4 — Panacea Innovation Ltd | View Filing | |
| form 4 | Form 4 — Huang James | View Filing | |
| edgar index | 8-K — Atara Biotherapeutics, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | DEFA14A — Atara Biotherapeutics, Inc. | View Filing | |
| edgar index | DEF 14A — Atara Biotherapeutics, Inc. | View Filing | |
| edgar index | 424B3 — Atara Biotherapeutics, Inc. | View Filing | |
| edgar index | EFFECT — Atara Biotherapeutics, Inc. | View Filing | |
| edgar index | CORRESP — Atara Biotherapeutics, Inc. | View Filing | |
| edgar index | UPLOAD — Atara Biotherapeutics, Inc. | View Filing | |
| edgar index | 4 — Atara Biotherapeutics, Inc. | View Filing | |
| edgar index | S-3 — Atara Biotherapeutics, Inc. | View Filing | |
| form 4 | Form 4 — Panacea Innovation Ltd | View Filing | |
| form 4 | Form 4 — Panacea Innovation Ltd | View Filing | |
| form 4 | Form 4 — Huang James | View Filing | |
| form 4 | Form 4 — Huang James | View Filing | |
| form 4 | Form 4 — Panacea Innovation Ltd | View Filing | |
| form 4 | Form 4 — Huang James | View Filing | |
| form 4 | Form 4 — Panacea Innovation Ltd | View Filing | |
| form 4 | Form 4 — Huang James | View Filing | |
| edgar index | 8-K — Atara Biotherapeutics, Inc. | View Filing | |
| edgar index | 10-K — Atara Biotherapeutics, Inc. | View Filing | |
| edgar index | 424B5 — Atara Biotherapeutics, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| ten k section | 10-K — business | View Filing | |
| ten k section | 10-K — mda | View Filing | |
| ten k section | 10-K — risk_factors | View Filing | |
| edgar index | 8-K — Atara Biotherapeutics, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 4 — Atara Biotherapeutics, Inc. | View Filing | |
| edgar index | 4 — Atara Biotherapeutics, Inc. | View Filing | |
| form 4 | Form 4 — Grant-Huerta Yanina | View Filing | |
| form 4 | Form 4 — Nguyen AnhCo | View Filing | |
| edgar index | 4 — Atara Biotherapeutics, Inc. | View Filing | |
| edgar index | 4 — Atara Biotherapeutics, Inc. | View Filing | |
| edgar index | 8-K — Atara Biotherapeutics, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 144 — Atara Biotherapeutics, Inc. | View Filing | |
| edgar index | 144 — Atara Biotherapeutics, Inc. | View Filing | |
| form 4 | Form 4 — Nguyen AnhCo | View Filing | |
| form 4 | Form 4 — Nguyen AnhCo | View Filing | |
| form 4 | Form 4 — Nguyen AnhCo | View Filing | |
| form 4 | Form 4 — Nguyen AnhCo | View Filing | |
| form 4 | Form 4 — Grant-Huerta Yanina | View Filing | |
| form 4 | Form 4 — Grant-Huerta Yanina | View Filing | |
| form 4 | Form 4 — Grant-Huerta Yanina | View Filing | |
| form 4 | Form 4 — Grant-Huerta Yanina | View Filing | |
| edgar index | 8-K — Atara Biotherapeutics, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 4 — Atara Biotherapeutics, Inc. | View Filing |